Tilray Brands reported Q3 2026 revenue of $206.7 million, an 11% year‑over‑year increase that surpassed the consensus estimate of $205.93 million. The jump was driven largely by a 73% rise in international cannabis revenue and an 8% rise in Canadian adult‑use and medical cannabis, while beverage revenue fell to $42.6 million from $55.9 million in the prior year.
The company posted an adjusted earnings per share of $0.02, a miss relative to the consensus expectation of a $0.14 loss. The miss was largely attributable to higher operating expenses and a one‑time non‑cash impairment recorded in the prior year, which reduced profitability.
Gross profit increased to $55 million, a 6% year‑over‑year gain, but the consolidated gross margin contracted to 27% from 28% because beverage gross margin fell to 32% from 36% and distribution costs rose.
Management reaffirmed its FY2026 adjusted EBITDA guidance of $62 million to $72 million, unchanged from the prior guidance. The steady guidance signals confidence that the company’s global strategy will continue to generate earnings momentum despite the EPS miss.
Segment performance highlights that distribution net revenue grew 35% year‑over‑year to $83 million, while beverage revenue declined, reflecting cost‑saving restructuring. International cannabis remains the strongest growth driver, underscoring the company’s focus on expanding its global footprint.
Investors focused on the EPS miss, which outweighed the revenue beat. Analysts noted that the revenue growth was offset by margin compression and the EPS miss, tempering enthusiasm for the quarter’s results.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.